As filed with the Securities and Exchange Commission on April 2, 2024. 

Registration No. 333-278006

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 

Washington, D.C. 20549

 

Amendment No. 1 to

 

FORM S-1

 

REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

 

MUSTANG BIO, INC. 

(Exact name of registrant as specified in its charter)

 

Delaware
(State or other jurisdiction of
incorporation or organization)
  2836
(Primary Standard Industrial
Classification Code Number)
  47-3828760
(I.R.S. Employer
Identification Number)

 

377 Plantation Street 

Worcester, Massachusetts 01605 

(781) 652-4500 

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Manuel Litchman, M.D. 

President and Chief Executive Officer 

377 Plantation Street 

Worcester, Massachusetts 01605 

(781) 652-4500 

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

Copies to:

 

Rakesh Gopalan 

Joseph Walsh 

Troutman Pepper Hamilton Sanders LLP 

301 S. College Street, 34th Floor 

Charlotte, NC 28202 

(704) 998-4050​

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. x

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨ 

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨ 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨   Accelerated filer ¨ 
Non-accelerated filer x    Smaller reporting company x 
    Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

 

The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

 

 

 

 

 

 

EXPLANATORY NOTE

 

Mustang Bio, Inc. is filing this Amendment No. 1 (this “Amendment”) to its Registration Statement on Form S-1 (File No. 333-278006) (the ‘‘Registration Statement”) solely to file Exhibits 1.4, 4.8, 4.9, 4.10 and 10.40. Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 16(a) of Part II of the Registration Statement, the exhibit index to the Registration Statement, the signature page to the Registration Statement and the exhibits filed herewith. The prospectus, constituting Part I of the Registration Statement, is unchanged and therefore has been omitted from this filing.

 

 

 

 

PART II

 

INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 16. Exhibits and Financial Statement Schedules.

 

The exhibits listed below are filed as part of this registration statement.

 

Exhibit No. Description Form File Number Date Exhibit No. Filed
Herewith
1.1 At Market Issuance Sales Agreement, dated July 27, 2018, between the Company, B. Riley FBR, Inc., Cantor Fitzgerald & Co., National Securities Corporation, and Oppenheimer & Co. Inc. 8-K 001-38191 July 27, 2018 1.1  
1.2 Amendment No. 1 to At Market Issuance Sales Agreement, dated July 20, 2020, between the Company, B. Riley FBR, Inc., Cantor Fitzgerald & Co., National Securities Corporation and Oppenheimer & Co. Inc. 8-K 001-38191 July 24, 2020 1.2  
1.3 Amendment No. 2 to At Market Issuance Sales Agreement, dated December 31, 2020, between the Company, B. Riley Securities, Inc., Cantor Fitzgerald & Co., National Securities Corporation, Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC. (incorporated by reference to the Exhibit 1.1 of the Registrant’s Current Report on Form 8-K (file No. 001-38191) filed with the SEC on December 31, 2020). 8-K 001-38191 December 31, 2020 1.1  
1.4 Amendment No. 3 to At Market Issuance Sales Agreement, dated April 14, 2023, between the Registrant B. Riley Securities, Inc., Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC 8-K 001-38191 April 20, 2023 1.1  

 

 

 

 

2.1 Asset Purchase Agreement, dated May 18, 2023, between the Company and uBriGene (Boston) Biosciences, Inc. # 8-K 001-38191 May 22, 2023 1.1  
2.2 First Amendment to Asset Purchase Agreement, dated June 29, 2023, between the Company and uBriGene (Boston) Biosciences, Inc. 8-K 001-38191 June 30, 2023 2.2  
2.3 Second Amendment to Asset Purchase Agreement, dated July28, 2023, between the Company and uBriGene (Boston) Biosciences, Inc. 8-K 001-38191 July 31, 2023 2.3  
3.1 Amended and Restated Certificate of Incorporation of Mustang Bio, Inc. (formerly Mustang Therapeutics, Inc.), dated July 26, 2016 10-12G 000-5568 July 28, 2016 3.1  
3.2 Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Mustang Bio, Inc., dated June 14, 2018 10-Q 001-38191 August 13, 2018 3.1  
3.3 Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Mustang Bio, Inc., dated September 30, 2019 8-K 001-38191 September 30, 2019 3.1  
3.4 Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Mustang Bio, Inc., dated December 4, 2020 8-K 001-38191 December 4, 2020 3.1  

 

 

 

 

3.5 Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Mustang Bio, Inc., dated June 17, 2021 8-K 001-38191 June 22, 2021 3.1  
3.6 Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Mustang Bio, Inc., dated July 5, 2022 8-K 001-38191 July 7, 2022 3.1  
3.7 Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Mustang Bio, Inc., dated April 3, 2023 8-K 001-38191 April 3, 2023 3.1  
3.8 Amended and Restated Bylaws of Mustang Bio, Inc. 8-K 001-38191 April 3, 2023 3.2  
4.1 Specimen certificates evidencing shares of common stock, Class A common stock and Class A preferred stock 10-12G 000-5568 July 28, 2016 4.1  
4.2 Form of Warrant Agreement 10-12G 000-5568 July 28, 2016 4.2  
4.3 Common Stock Warrant issued by Mustang Bio, Inc. to NSC Biotech Venture Fund I, LLC, dated July 5, 2016 10-12G 000-5568 July 28, 2016 10.5  
4.4 Warrant to Purchase Common Stock issued to Runway Growth Finance Corp., dated March 4, 2022 8-K 001-3891 March 8, 2022 4.1  
4.5 Form of Pre-funded Warrant 8-K 001-38191 October 30, 2023 4.1  
4.6 Form of Warrant 8-K 001-38191 October 30, 2023 4.2  
4.7 Form of Wainwright Warrant 8-K 001-38191 October 30, 2023 4.3  
4.8 Form of Pre-Funded Warrant offered hereby          X

 

 

 

 

4.9 Form of Warrant offered hereby        
4.10 Form of Placement Agent Warrant        
5.1* Opinion of Troutman Pepper Hamilton Sanders LLP          
10.1 Second Amended and Restated Founders Agreement between Fortress Biotech, Inc. and Mustang Bio, Inc., dated July 26, 2016 10-12G 000-5568 July 28, 2016 10.1  
10.2 Management Services Agreement between Fortress Biotech, Inc. and Mustang Bio, Inc., dated March 13, 2015 10-12G 000-5568 July 28, 2016 10.2  
10.3 Future Advance Promissory Note to Fortress Biotech, Inc., dated May 5, 2016 10-12G 000-5568 July 28, 2016 10.3  
10.4 Promissory Note to NSC Biotech Venture Fund I, LLC, dated July 5, 2016 10-12G 000-5568 July 28, 2016 10.4  
10.5 License Agreement by and between Mustang Bio, Inc. and City of Hope, dated March 17, 2015 # 10-12G 000-5568 July 28, 2016 10.6  
10.6 Sponsored Research Agreement by and between Mustang Bio, Inc. and City of Hope, dated March 17, 2015 10-12G 000-5568 July 28, 2016 10.7  
10.7 Agreement by and between Mustang Bio, Inc. and Chord Advisors, LLC, dated April 8, 2016 10-12G 000-5568 July 28, 2016 10.10  
10.8 Board Advisory Services Agreement by and between Mustang Bio, Inc. and Caribe BioAdvisors, LLC 10-K 000-5568 March 31, 2017 10.11  
10.9 Exclusive License Agreement by and between Mustang Bio, Inc. and The Regents of the University of California, dated March 17, 2017 # 10-Q 000-5568 August 14, 2017 10.4  

 

 

 

 

10.10 Exclusive License Agreement (IV/ICV) by and between Mustang Bio, Inc. and City of Hope, dated February 17, 2017 # 10-Q 000-55668 August 14, 2017 10.5  
10.11 Amended and Restated Exclusive License Agreement (CD123) by and between Mustang Bio, Inc. and City of Hope, dated February 17, 2017 # 10-K 001-3891 March 31, 2017 10.14  
10.12 Amended and Restated Exclusive License Agreement (IL13Ra2) by and between Mustang Bio, Inc. and City of Hope, dated February 17, 2017 # 10-K 000-5568 March 31, 2017 10.15  
10.13 Amended and Restated Exclusive License Agreement (Spacer) by and between Mustang Bio, Inc. and City of Hope, dated February 17, 2017 # 10-K 000-5568 March 31, 2017 10.16  
10.14 Employment Agreement between Manuel Litchman and Mustang Bio, Inc., effective as of April 24, 2017  8-K 000-5568 April 24, 2017 10.1  
10.15 License Agreement (CSI) by and between Mustang Bio, Inc. and City of Hope, dated May 31, 2017 # 10-Q/A 001-38191 November 14, 2017 10.1  
10.16 License Agreement (PSCA) by and between Mustang Bio, Inc. and City of Hope, dated May 31, 2017 # 10-Q/A 001-38191 November 14, 2017 10.2  
10.17 License Agreement (HER2) by and between Mustang Bio, Inc. and City of Hope, dated May 31, 2017 # 10-Q/A 001-38191 November 14, 2017 10.3  

 

 

 

 

10.18 Lease Agreement by and between Mustang Bio, Inc. and WCS - 377 Plantation Street, Inc., dated October 27, 2017 10-Q 001-3891 November 14, 2017 10.1  
10.19 Sublease Agreement by and between Mustang Bio, Inc., and The Paul Reverse Life Insurance Company, dated June 14, 2022 10-K 001-3891 March 30, 2023 10.22  
10.20 First Amendment to Sublease Agreement by and between Mustang Bio, Inc. and The Paul Revere Life Insurance Company, dated October 25, 2022 10-K 001-3891 March 30, 2023 10.23  
10.21 Second Amendment to Sublease, dated April 27, 2023, between the Company and The Paul Revere Life Insurance Company 8-K 001-38191 July 20, 2023 10.2  
10.22 Third Amendment to Sublease, dated June 15, 2023, between the Company and The Paul Revere Life Insurance Company 8-K 001-38191 July 20, 2023 10.3  
10.23 Mustang Bio, Inc. 2016 Incentive Plan † 10-12G 000-5568 July 28, 2016 10.8  
10.24 Mustang Bio, Inc. Non-Employee Directors Compensation Plan  10-12G 000-5568 July 28, 2016 10.9  
10.25 Amendment to Mustang Bio, Inc. 2016 Incentive Plan DEF 14A 001-3891 April 30, 2018 N/A  
10.26 Second Amendment to the Mustang Bio, Inc. 2016 Equity Incentive Plan, dated June 17, 2021  8-K 001-3891 June 22, 2021 10.1  
10.27 Third Amendment to Mustang Bio, Inc. 2016 Equity Incentive Plan, dated June 21, 2022  8-K 001-3891 June 24, 2022 10.1  
10.28 Form of Option Agreement under the Mustang Bio, Inc. 2016 Incentive Plan 10-K 001-3891 March 11, 2024 10.28  

 

 

 

 

10.29 Form of Restricted Stock Unit Agreement under the Mustang Bio, Inc. 2016 Incentive Plan 10-K 001-3891 March 11, 2024 10.29  
10.30 Form of Director Stock Award Agreement under the Mustang Bio, Inc. Non-Employee Directors Compensation Plan 10-K 001-3891 March 11, 2024 10.30  
10.31 Mustang Bio, Inc. 2019 Employee Stock Purchase Plan  10-Q 001-3891 August 9, 2019 10.1  
10.32 Amendment to the Mustang Bio, Inc. 2019 Employee Stock Purchase Plan, dated June 17, 2021  8-K 001-3891 June 22, 2021 10.2  
10.33 Amendment No. 2 to the Mustang Bio, Inc. 2019 Employee Stock Purchase Plan, dated June 21, 2023 † 8-K 001-3891 June 21, 2023 10.1  
10.34 Loan and Security Agreement by and between Mustang Bio, Inc., the Borrower, the Lenders, and Runway Growth Finance Corp. (as agent), dated March 4, 2022 8-K 001-38191 March 8, 2022 99.1  
10.35 First Amendment to Loan and Security Agreement by and between Mustang Bio, Inc., the Borrower, the Lenders and Runway Growth Finance Corp. (as agent), dated December 7, 2022 8-K 001-38191 December 13, 2022 10.1  
10.36 Consulting Agreement by and between Mustang Bio, Inc. and Danforth Advisors, LLC dated March 17, 2022 8-K 001-38191 April 22, 2022 99.1  

 

 

 

 

10.37 Manufacturing Services Agreement, dated July 28, 2023, between the Company and uBriGene (Boston) Biosciences, Inc. 8-K 001-38191 July 31, 2023 10.1  
10.38 Sub-Contracting Manufacturing Services Agreement, dated July 28, 2023, between the Company and uBriGene (Boston) Biosciences, Inc. 8-K 001-38191 July 31, 2023 10.2  
10.39 Form of Securities Purchase Agreement, dated October 26, 2023, by and between the Company and the purchaser party thereto 8-K 001-38191 October 30, 2023 10.1  
10.40 Form of Securities Purchase Agreement         X
23.1^ Consent of Independent Registered Public Accounting Firm, KPMG LLP          
23.2* Consent of Troutman Pepper Hamilton Sanders LLP (included in Exhibit 5.1)          
24.1^ Power of Attorney          
107^ Filing Fee Table          

 

# Portions of this Exhibit have been omitted pursuant to Item 601(b)(1)(iv) of Regulation S-K.

 

† Management contract or compensatory plan.​

 

* To be filed by amendment.

 

^ Previously filed.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Worcester, Commonwealth of Massachusetts, on this 2nd day of April, 2024.

 

  MUSTANG BIO, INC.
   
  By: /s/ Manuel Litchman, M.D.
  Manuel Litchman, M.D.
  Chief Executive Officer and President

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature   Title   Date
/s/ Manuel Litchman   President, Chief Executive Officer and Director    
Manuel Litchman, M.D.   (Principal Executive Officer)   April 2, 2024
         
/s/ James Murphy   Interim Chief Financial Officer    
James Murphy   (Principal Financial and Accounting Officer)   April 2, 2024
         
*    Chairman of the Board of Directors and Executive    
Michael S. Weiss   Chairman   April 2, 2024
         
*        
Adam Chill   Director   April 2, 2024
         
*        
Neil Herskowitz   Director   April 2, 2024
         
*        
Lindsay A. Rosenwald, M.D.   Director   April 2, 2024
         
*        
Michael Zelefsky, M.D.   Director   April 2, 2024

 

*By:   /s/ James Murphy  
    James Murphy  
    Attorney-in-fact